ELISA Kit for Galectin 3 (GAL3)

0.156-10ng/mL

The minimum detectable dose of this kit is typically less than 0.060ng/mL

3h

This assay has high sensitivity and excellent specificity for detection of Galectin 3 (GAL3).
No significant cross-reactivity or interference between Galectin 3 (GAL3) and analogues was observed.

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Galectin 3 (GAL3). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Galectin 3 (GAL3). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Galectin 3 (GAL3), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Galectin 3 (GAL3) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Galectin-1 and galectin-3: plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population; Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension; The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension; Galectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices; Galectin-1 and galectin-4: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population; Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4.; Can we define migraine patients with blood high-sensitivity C-reactive protein and galectin-3 levels in the emergency department?; A sensitive sandwich-type immunosensor for the detection of galectin-3 based on N-GNRs-Fe-MOFs@AuNPs nanocomposites and a novel AuPt-methylene blue nanorod.; The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction.; Galectin-3 in patients with coronary heart disease and atrial fibrillation; Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary Disease; Signature-oriented investigation of the efficacy of multicomponent drugs against heart failure;